Ipca Laboratories is currently trading at Rs. 959.70, up by 2.05 points or 0.21 % from its previous closing of Rs. 957.65 on the BSE.
The scrip opened at Rs. 950.00 and has touched a high and low of Rs. 970.00 and Rs. 950.00 respectively.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1042.00 on 29-Mar-2019 and a 52 week low of Rs. 590.10 on 11-Oct-2018.
Last one week high and low of the scrip stood at Rs. 970.00 and Rs. 932.90 respectively. The current market cap of the company is Rs. 12100.11 crore.
The promoters holding in the company stood at 46.07%, while Institutions and Non-Institutions held 39.65% and 14.28% respectively.
US Food and Drug Administration (USFDA) has completed the inspection at Ipca Laboratories’ Formulations manufacturing Unit situated at Piparia (Silvassa). The agency has conducted operations from August 19, 2019 to August 23, 2019. At the conclusion of the inspection, the USFDA issued a Form 483 with 3 observations.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.